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Background Transcatheter aortic valve implantation (TAVI) has emerged as a new therapeutic option in high-risk patients with
severe aortic stenosis.
Aims PARTNER EU is the ﬁrst study to evaluate prospectively the procedural and mid-term outcomes of transfemoral (TF)
or transapical (TA) implantation of the Edwards SAPIENw valve involving a multi-disciplinary approach.
Methods
and results
Primary safety endpoints were 30 days and 6 months mortality. Primary efﬁcacy endpoints were haemodynamic and
functional improvement at 12 months. One hundred and thirty patients (61 TF, 69 TA), aged 82.1+5.5 years were
included. TA patients had higher logistic EuroSCORE (33.8 vs. 25.7%, P ¼ 0.0005) and more peripheral disease (49.3
vs. 16.4%, P , 0.0001). Procedures were aborted in four TA (5.8%) and six TF cases (9.8%). Valve implantation was
successful in the remaining patients in 95.4 and 96.4%, respectively. Thirty days and 6 months survival were 81.2 and
58.0% (TA) and 91.8 and 90.2% (TF). In both groups, mean aortic gradient decreased from 46.9+18.1 to
10.9+5.4 mmHg 6 months post-TAVI. In total, 78.1 and 84.8% of patients experienced signiﬁcant improvement
in New York Heart Association (NYHA) class, whereas 73.9 and 72.7% had improved Kansas City Cardiomyopathy
Questionnaire (KCCQ) scores in TA and TF cohorts, respectively.
Conclusion This ﬁrst team-based multi-centre European TAVI registry shows promising results in high-risk patients treated by TF
or TA delivery. Survival rates differ signiﬁcantly between TF and TA groups and probably reﬂect the higher risk proﬁle
of the TA cohort. Optimal patient screening, approach selection, and device reﬁnement may improve outcomes.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Degenerative aortic stenosis is the most commonly acquired valv-
ular heart disease in adults. Its prevalence is  4% in patients over
80 years of age and due to population ageing, the absolute number
of patients should continue to increase. In symptomatic patients,
surgical aortic valve replacement (AVR) has been the treatment
of choice for .40 years.
1 However, among the elderly, up to
30–60%
2–4 of cases are considered too high risk for open-heart
surgery. Transcatheter aortic valve implantation (TAVI) initially
described by Andersen
5 was introduced for non-operable patients
by Cribier in 2002.
6 The transeptal approach used was technically
demanding and in 2005 Webb
7 introduced an arterial retrograde
transfemoral (TF) delivery system. A transapical (TA) off-pump
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8 The Edwards
SAPIEN
w transcatheter heart valve (THV) used in this study
(Edwards Lifesciences Irvine, CA, USA) is a second generation
bovine pericardial balloon-expandable prosthesis available in 23
and 26 mm sizes for native aortic annuli diameters between 18
and 25 mm. The TF delivery system is suitable for ileo-femoral
vessels with a diameter ≥7 mm for the 22 Fr and ≥8 mm for
the 24 Fr sheath. The TA approach incorporates a shorter and
larger diameter (33 Fr) delivery system compatible with the 23
or 26 mm Edwards SAPIENTM valve.
The aim of the PARTNER EU trial was to prospectively establish
the role of both TF and TA in this high-risk population. This paper
reports the 30 day, 6 month, and 1 year results of this study.
Methods
Patients with severe aortic stenosis underwent joint interdisciplinary
screening by a dedicated local team to determine study eligibility.
They were prospectively enrolled between April 2007 and January
2008 in a non-randomized, multi-centre European prospective study.
Because this study was intended as a landmark report, the majority
of centres were in the learning phase and 4 of 9 centres (44.4%)
carried out their ﬁrst TAVI cases on the occasion of the study. The
implant approach (TA or TF) was selected following review of the
patients’ screening data according to the local TAVI team’s experience.
There were no guidelines given to the team recommending one type
of procedure or another, as the decision to utilize the TF or the TA
approach involves myriad factors, including assessment of access
vessel size and the tortuosity of those vessels, the amount of disease
in the peripheral vasculature and its speciﬁc characteristics, as well
as other factors, such as respiratory status, that may predispose to a
TF or TA approach.
In adjudicating events, the members of the Clinical Events Committee
were not blinded to the implant approach. This study complies with the
declarationofHelsinki.Ethicscommitteeapprovalwasobtainedinallpar-
ticipating centres prior to commencement of the study. All subjects pro-
vided written informed consent to participate in the study.
Inclusion/exclusion criteria
Main inclusion criteria were severe, symptomatic, degenerative aortic
stenosis, with an effective oriﬁce area (EOA) ,0.8 cm
2 (or indexed
,0.6 cm
2) or mean gradient .40 mmHg (or jet velocity .4.0 m/s),
New York Heart Association (NYHA) Functional Class ≥II, logistic
EuroSCORE ≥20, or Society of Thoracic Surgeons Score (STS
Score) ≥10 or surgical contra indications such as porcelain aorta,
prior thoracic radiation therapy, or severe chest deformities.
Mainexclusioncriteriawerenativeaorticannulussize,18or.25 mm
by transoesophageal echo (TEE), acute myocardial infarction ,14 days,
unprotectedleftmaindisease.70%,anytherapeuticinvasivecardiacpro-
cedureotherthanballoonvalvuloplastywithin30days,activeinfection,life
expectancy ,12 months, primary hypertrophic obstructive cardiomyo-
pathy, haemodynamic instability, severe neurological disease, renal
failure, preexisting prosthetic heart valve, or thoracic aneurysm.
Study endpoints
The primary safety endpoints were freedom from death at 30 days and
6 months. The primary efﬁcacy endpoints were haemodynamic, NYHA
class and quality of life (QoL) improvement at 12 months. Clinical and
echocardiographic data were obtained at baseline, before discharge,
and at 30 days, 6 months, and 1 year.
Quality of life questionnaires using the EuroQol with EQ-5D
UK-TTO rating scale
9 and Kansas City Cardiomyopathy Questionnaire
(KCCQ)
10 were assessed at baseline and at all follow-up intervals to
1 year. Outcomes were described according to the guidelines for
reporting mortality and morbidity after cardiac valve intervention.
11
All events related to primary and secondary endpoints were adjudi-
cated by an independent clinical events committee.
Study deﬁnitions
Cardiac death was deﬁned as death resulting from any cardiac causes
or any sudden unexplained deaths.
Device Success was deﬁned as successful delivery and deployment
of the device and retrieval of the delivery catheter resulting in an
aortic valve area greater than 0.9 cm
2 with 2+ (moderate) or less
aortic regurgitation (AR) in the earliest evaluable echocardiogram
and only one valve implanted in the correct anatomical position.
A stroke was deﬁned as follows: focal neurological deﬁcit lasting
≥24 h or focal neurological deﬁcit lasting ,24 h with imaging ﬁndings
of acute infarction or haemorrhage.
Stroke was further classiﬁed as ischaemic, haemorrhagic, or ischae-
mic with haemorrhagic conversion.
Vascular complications were deﬁned as a haematoma .5 cm at the
access site, false aneurysm, arterio-venous ﬁstula, retroperitoneal
bleeding, peripheral ischaemia, nerve injury, transfusion except for
indications clearly other than catheterization complications,
unplanned vascular surgical repair, annular dissection, aortic dissection
or thoracic wound complication. Any event which was not a major
complication was considered a minor event. Major vascular compli-
cations were deﬁned as any access-related vascular injury leading to
either death, need for signiﬁcant blood transfusions (.3 units),
unplanned percutaneous or surgical intervention, ischaemia, neuro-
logical impairment or irreversible end-organ damage, and left ventri-
cular perforation.
Bleeding events were deﬁned according to the TIMI deﬁnition
as major or minor. They included surgical bleeding, haemorrhage,
cardiac tamponade, or need for transfusion.
Valve deployment time was deﬁned as the time from balloon valvu-
loplasty to deployment of the valve.
Procedure
Transfemoral procedures were performed under conscious sedation
or general anaesthesia and TEE at the discretion of the team. After ret-
rograde pre-dilation of the native valve, THV was advanced by the
RetroFlexTM catheter, positioned within the native aortic valve, and
then delivered by balloon inﬂation under rapid ventricular pacing
(RVP). For the TA procedure a left anterolateral mini-thoracotomy
and pericardiotomy were performed, and a double pledgeted purse-
string suture or U stitches were placed at the left ventricular apex.
After puncture of the apex, antegrade crossing, and pre-dilatation,
THV was deployed under RVP. Transoesophagal echo was used at
the discretion of the team.
Statistical analysis
Patient data were analysed according to the intention-to-treat (ITT)
principle. Comparison of baseline factors between TF and TA patients
used Wilcoxon signed rank tests for continuous variables or Pearson’s
Chi-square tests for categorical variables. Early (≤30 days) events
were summarized as percentages. Survival was estimated at 30 days,
6 months, and 1 year using the method of Kaplan and Meier. The pro-
cedure day was considered ‘day 0.’ A logistic regression model was ﬁt
with 1 year survival and Logistic Euroscore as the dependent and
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with a 4-knot natural spline in this model to allow a ﬂexible association
between the risk score and 1 year mortality. The statistical signiﬁcance
of this effect was investigated via a likelihood ratio statistic. A similar
logistic regression analysis was performed for the STS score.
In order to declare device success for a given patient, a discharge or
30 day value for both EOA and AI was required. The percentage of
subjects experiencing NYHA improvement at 1 year relative to base-
line was based on all subjects that had a recorded NYHA value at both
baseline and 1 year follow-up. For the KCCQ score, a patient was
classiﬁed as improved if he experienced an increase ≥5 points over
baseline.
12 Percentage of patients improved was calculated for patients
.........................................................................................................................
Table 1 Number of patients enrolled per centre (does not include one screening
failure)
Transapical Transfemoral Total
AKH, Wien 10 9 19
Hopital Bichat, Paris 9 9 18
Kings College Hospital, London 10 7 17
West-German Heart Center University Hospital, Essen 10 6 16
Institut Hospitalier Jacques Cartier, Massy 5 10 15
Onze Lieve Vrouwziekenhuis (OLVZ), Aalst 5 8 13
Hopital Charles Nicolle, Rouen 5 7 12
J.W. Goethe University, Frankfurt 10 2 12
Erasmus MC, Rotterdam 5 3 8
Total 69 61 130
...............................................................................................................................................................................
Table 2 Baseline characteristics by delivery approach
Characteristics Overall (n 5 130) Transapical (n 5 69) Transfemoral (n 5 61) P-value
Age, years 82.1+5.5 (67.7–93.3) 81.9+5.7 (67.7–93.3) 82.3+5.2 (69.1–92.5) 0.7194
Female gender (%) 72 (55.4) 35 (50.7) 37 (60.7) 0.2556
NYHA (%) 0.9920
Class I 2 (1.5) 1 (1.4) 1 (1.6)
Class II 18 (13.8) 9 (13.0) 9 (14.8) —
Class III 88 (67.7) 47 (68.1) 41 (67.2) —
Class IV 22 (16.9) 12 (17.4) 10 (16.4) —
Diabetes (%) 41 (31.5) 20 (29.0) 21 (34.4) 0.5053
Coronary artery disease (%) 78 (60.0) 45 (65.2) 33 (54.1) 0.1965
Myocardial infarction (%) 27 (20.8) 14 (20.3) 13 (21.3) 0.8861
Mitral valve disease (%) 68 (52.3) 43 (62.3) 25 (41.0) 0.0151
Carotid disease 31 (23.8) 23 (33.3) 8 (13.1) 0.0069
High blood pressure (%) 96 (73.8) 53 (76.8) 43 (70.5) 0.4132
Previous PCI (%) 32 (24.6) 18 (26.1) 14 (23.0) 0.6787
Previous CABG (%) 41 (31.5) 29 (42.0) 12 (19.7) 0.0062
Peripheral disease (non-carotid) (%) 44 (33.8) 34 (49.3) 10 (16.4) ,0.0001
Atrial ﬁbrillation (%) 32 (24.6) 17 (24.6) 15 (24.6) 0.9950
Previous pace-maker (%) 17 (13.1) 11 (15.9) 6 (9.8) 0.3028
AV Block (%) 21 (16.2) 10 (14.5) 11 (18.0) 0.5842
Renal failure (%) 54 (41.5) 32 (46.4) 22 (36.1) 0.2338
Pulmonary disease (%) 54 (41.5) 24 (34.8) 30 (49.2) 0.0964
Cancer (%) 19 (14.6) 9 (13.0) 10 (16.4) 0.5895
EOA (cm
2) 0.6+0.2 (0.3–1.2) 0.6+0.2 (0.3–1.2) 0.6+0.2 (0.3–1.1) 0.4732
Mean gradient (mmHg) 47.3+18.9 (18.0–120.0) 46.6+18.6 (18.0–87.0) 48.0+19.4 (18.0–120.0) 0.6744
LVEF (%) 52.8+16.1 (15.0–86.1) 52.8+14.6 (17.3–77.0) 52.9+17.8 (15.0–86.1) 0.7712
Logistic EuroSCORE (%) 30.0+13.7 (5.1–72.1) 33.8+14.4 (5.1–72.1) 25.7+11.5 (6.4–65.5) 0.0005
STS-score (%) 11.6+6.5 (2.0–41.0) 11.8+6.8 (2.0–41.0) 11.3+6.1 (3.7–32.7) 0.7994
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as the minimum clinically important difference.
9 A Wilcoxon test was
performed on paired differences between 1 year and baseline KCCQ
and EQ-5D in patients with baseline and 1 year data using 0.05 as the
minimum clinically important difference.
9 For EOA, mean gradient, and
LVEF the mean and standard deviation were calculated at baseline, 6
months, and 1 year. For each of these parameters, a Wilcoxon test
was performed on the paired differences between 6 months and base-
line for patients with data available at both time points. All analyses
were carried out using the SAS version 9.1.2 and Splus version 8.
Medication regimens
It was recommended that all patients receive aspirin and thienopyridine
prior to procedure and continue thienopyridine for 6 months post-
procedure and aspirin indeﬁnitely. A bolus of 5000 units of heparin
was injected when starting the procedure and monitoring was per-
formedtokeepthepatient’sACT .250 s.Post-dischargeantibioticpro-
phylaxis for endocarditis was recommended according to the most
recent guidelines of the American Heart Association.
13
Results
Patients were included from April 2007 to January 2008. Informed
consents were signed by 131 patients. In one patient, TAVI was not
attempted due to active endocarditis which was diagnosed after
inclusion in the study.
Demographics and baseline
characteristics
Of the remaining 130 patients, 61 were scheduled to receive a TF
and 69 a TA intervention. Distribution of TF and TA approach
according to centre is shown in Table 1. Patient clinical and echo-
cardiographic characteristics are summarized in Table 2. After
Bonferroni adjustment, the only signiﬁcant differences between
TA and TF patients were logistic EuroSCORE (33.8+14.4 vs.
25.7+11.5%, P ¼ 0.0109) and peripheral disease (49.3 vs.
16.4%, P ¼ 0.0018).
Figure 1 Procedural outcome.
................................................................................
Table 3 Procedural characteristics by delivery
approach
Transfemoral Transapical
Deployment time (min) 30.7+18.0
(range: 7–120)
11.4+5.1
(range: 2–26)
Contrast volume (mL) 212.5+121.8
(range: 50–620)
153.8+76.7
(range: 50–370)
Total procedure time (min) 145.3+61.3
(range: 26–361)
131.6+59.3
(range: 35–475)
Procedure to discharge
(median days)
8
(range: 0–77)
11
(range: 0–59)
Total ICU (median days) 1
(range: 0–77)
1
(range: 0–56)
One year follow-up of the multi-centre PARTNER study 151Procedural outcomes
Procedural outcome and characteristics are summarized in Figure 1
and Table 3. Implantation of the Edwards SAPIENTM THV was
attempted in 61 TF and 69 TA patients. Transfemoral procedures
were aborted in six patients (9.8%), due to access failure in three
cases. One of these patients was treated by the TA approach 49
days later and remains alive and well. The two other patients
have had no reported adverse events. A fourth procedure was
aborted due to unsuccessful balloon dilatation. The patient was
successfully converted to surgical AVR with no further reported
adverse events. There was one case of inability to cross the
valve. The procedure was stopped and the patient has had no
further reported adverse events. Finally, one patient who suffered
refractory arrhythmia after balloon pre-dilatation went into cardiac
arrest as a result and died on the day of implant. In the remaining
55 patients, valve implantation (26, 23 mm and 29, 26 mm) was
successful in 53 (96.4%). Implant failure was related to ventricular
embolization in one case and aortic embolization in one. There
were no cases of coronary occlusion in the TF group.
Transapical procedures were aborted in four patients (5.8%).
There was one case of ventricular injury where the patient was suc-
cessfully converted to surgical AVR and remains well. In a second
case, the procedure was aborted due to severe septal hypertrophy.
The patient died 725 days later of respiratory failure. The third
patient had elevated C-reactive protein and died 320 days post-
procedure of cancer. The last patient in whom it was discovered
that the annulus was too large for the TH, had surgical AVR 15
days after the THV procedure and survived 534 days. The death
was reported as sudden. The valve was successfully implanted (21,
23 mm and 44, 26 mm) in 62 (95.4%) of the remaining 65 TA
patients. Implant failure was related to ventricular embolization in
one case, annulus dissection in one, and severe AR requiring
valve-in-valve deployment in one. There was one case of peri-
procedural coronary occlusion that occurred in the TA group
(1.4%), which was treated by a drug-eluting stent.
Thirty-day outcome
Thirty-day outcome as well as 6- and 12-month outcomes are sum-
marized in Table 4 for the TA group and Table 5 for the TF group.
Mortality was lower than predicted by the logistic EuroSCORE
(8.2% in the TF and 18.8% in the TA group). The rate of stroke
and atrioventricular block requiring pace-maker implantation was
low in both groups. Major bleeding events were more frequent in
theTAarm,whereasmajoraccesssitecomplicationsweremorefre-
quent in the TF arm. In the TF arm, 5 of 10 (50%) major access site
complications were dissection or damage to the vessel, followed by
iliac perforation (2), femoral perforation (1) and iliac artery stent
................................................................................
Table 4 Kaplan–Meier safety estimates
(non-hierachical ranking)—transapical patients
a
30 Days 6 Months 1 Year
Death 81.2% (13) 58.0% (29) 49.3% (35)
Stroke 98.5% (1) 92.4% (4) 89.7% (5)
Myocardial infarction 94.0% (4) 92.2% (5) 92.2% (5)
Coronary obstruction 98.6% (1) 98.6% (1) 98.6% (1)
Emergent aortic valve
replacement
97.1% (2) 97.1% (2) 94.5% (3)
Valve embolization 98.6% (1) 98.6% (1) 98.6% (1)
Structural valve
deterioration
100.0% (0) 100.0% (0) 100.0% (0)
New pacemaker 96.2% (2) 94.0% (3) 94.0% (3)
Vascular complications 95.3% (3) 91.2% (5) 91.2% (5)
Incidence at 30 days
b
overall
5.8% (4)
Major 5.8% (4)
Minor 0
Bleeding event 78.3% (14) 70.4% (18) 70.4% (18)
Incidence at 30 days
c
overall
20.3% (19)
Major 11.6% (8)
Minor 10.1% (7)
Undetermined 5.7% (4)
Renal failure (new
onset)
c
93.8% (2) 93.8% (2) 93.8% (2)
aUnless otherwise stated, numbers in parentheses refer to the number of patients
experiencing an event.
bHere incidence refersto the number of events (as opposed to number of patients
experiencing an event) divided by the number of patients.
cPatients with pre-existing renal failure are excluded from these estimates.
................................................................................
Table 5 Kaplan–Meier safety estimates
(non-hierachical ranking)—transfemoral patients
a
30 Days 6 Months 1 Year
Death 91.8% (5) 90.2% (6) 78.7% (13)
Stroke 96.7% (2) 94.9% (3) 93.0% (4)
Myocardial infarction 96.7% (2) 95.0% (3) 93.2% (4)
Coronary obstruction 100.0% (0) 100.0% (0) 100.0% (0)
Emergent aortic valve
replacement
98.4% (1) 98.4% (1) 98.4% (1)
Valve embolization 96.7% (2) 96.7% (2) 96.7% (2)
Structural valve
deterioration
100.0% (0) 100.0% (0) 100.0% (0)
New pacemaker 98.2% (1) 98.2% (1) 98.2% (1)
Vascular complications 71.6% (17) 71.6% (17) 71.6% (17)
Incidence at 30 days
b
overall
27.9% (17)
Major 16.4% (10)
Minor 11.5% (7)
Bleeding event 76.5% (14) 76.5% (14) 76.5% (14)
Incidence at 30 days
b
overall
23.0% (15)
Major 4.9% (3)
Minor 14.8% (9)
Undetermined 4.9% (3)
Renal failure (new
onset)
c
100.0% (0) 97.1% (1) 97.1% (1)
aUnless otherwise stated, numbers in parentheses refer to the number of patients
experiencing an event.
bHere incidence refers to the numberof events (as opposed to number of patients
experiencing an event) divided by the number of patients.
cPatients with pre-existing renal failure are excluded from these estimates.
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wound(2),haematoma(1),falseaneurysm(1),iliacstenosis(1),lym-
phatic ﬁstula (1), and minor dissection (1). No death related to vas-
cular complications occurred in the TF group. In the TA arm, there
was one annular dissection resulting in death, one thoracic wound
complication due to gauze being left in at the end of the procedure,
onecaseoffemoralarterysuturerupture,andonecaseoflegischae-
mia secondary to surgical canulation.
Six- and twelve-month outcome
Study compliance is summarized in Table 6. One-year Kaplan–
Meier survival curves in the TF and TA arms are shown in
Figure 2A and B, respectively. The causes of death from implant
to 1-year follow-up are summarized in Table 7.
An improvement in NYHA class was observed in 78.1% of
patients at 1 year in the TA group (Table 8) and 84.8% in the TF
group (Table 9).
Of the TF patients, KCCQ score improved in 72.7% (Table 10)
and EQ-5D in 51.6%. Among TA patients, KCCQ score improved
in 73.9% and EQ-5D in 60.0%.
There was one case of valve thrombosis in the TA group requir-
ing explant at Day 257.
14
Valve performance
Echocardiographic parameters are summarized in Table 11. In both
groups, there was a signiﬁcant reduction in the mean aortic gradi-
ent and increase in EOA. Post-implantation AR was similar in both
groups and improved at follow-up. At discharge, 53.0% of patients
had ≤1+ AR, 42.0% 2+, and 5% had ≥3+. At 1 year, 75.0% of
patients with available data had ≤1+ AR and 25.0% had 2+.
Discussion
As life expectancy continues to increase in industrialized countries,
so the incidence of degenerative aortic stenosis is expected to
increase in parallel.
15 However, many of these patients are ineligi-
ble or poor surgical candidates
16–18 and TAVI may provide an
alternative therapeutic approach. The PARTNER EU Trial is
intended as a landmark study, which concurrently evaluates for
the ﬁrst time both TF and TA implantation of the Edwards
SAPIENTM THV with the selection of the delivery approach deter-
mined in each centre by the heart team. A drawback inherent in all
studies of this nature is that the majority of centres commenced
their TAVI experience in PARTNER EU. Consequently, this study
describes all aspects of the learning phase, including patient selec-
tion and imaging as well as procedural tips and tricks. It is interest-
ing to note that the overall proportion of patients treated by the
TF approach was 46.9%, but this rate varied from 16.7 to 66.7%
according to the experience and preferences of the heart team
in each centre. Importantly, the ﬁndings from this study inﬂuenced
the nature and design of subsequent studies, including the random-
ized PARTNER US Study.
Implant success
The study shows that despite limited experience, TAVI either via
the TF or TA approach can be performed with a high rate of
implant success (96.4 and 95.4% per protocol, and 87 and 90%
................................................................................
Table 6 Study compliance at baseline, 30 days,
6 months, and 1 year
Baseline
(%)
30 Days
(%)
6 Months
(%)
1 Year
(%)
Follow-up 100.0
a 93.8 93.7 100.0
NYHA 100.0 77.7 79.4 95.2
Echo
b 100.0 87.6 83.0 82.7
KCCQ 89.2 59.8 64.2 78.0
EQ-5D 87.7 61.6 61.1 78.0
aFor baseline, ‘follow-up’ implies collection of baseline risk forms.
bPatients that did not receive the valve were not eligible for echo follow-up. It
should also be noted that in certain instances, some parameters are not evaluable
from the echocardiogram.
Figure 2 (A) Overall survival for transapical patients. (B) Overall survival for transfemoral patients.
One year follow-up of the multi-centre PARTNER study 153on an ITT basis for TF and TA, respectively), in this very high-risk
population. The procedure was aborted before valve implantation
in 7.7% of cases mainly due to technical problems or non-optimal
screening (difﬁcult femoral or apical access, annulus too large,
failure to cross the native valve, C-reactive protein elevation,
etc.). Overall, device success was 79% (TA) and 75% (TF).
Ongoing training for optimal screening and progressive experience
with the device and procedure, in addition to device and delivery
system downsizing should further increase the success rate.
Mortality prediction
The observed 30-day mortality of 8.2% in the TF group and 18.8%
in the TA group is lower than the predicted mortality rates calcu-
lated by the logistic EuroSCORE (25.7 and 33.8%, respectively).
These promising results are consistent with previous TAVI
series.
19–22 This suggests that even though the EuroSCORE prob-
ably overestimates the procedural mortality risk after TAVI,
23 it
also reﬂects the relative safety of the procedure either by the TF
or the TA approach in these high-risk patients. Logistic regression
analysis revealed a signiﬁcant association between 1 year mortality
and logistic Euroscore (P ¼ 0.0161) as shown in Figure 3. It may not
be appropriate to extrapolate EuroSCORE algorithms based on
operated patients to this TAVI population, the majority of which
was deemed inoperable, and other clinical and morphological vari-
ables which are not captured by this score may play an important
role in risk assessment. Despite being more precise, the STS score
was not associated with the 1 year mortality rate in this study
(P ¼ 0.8515).
Differences in survival outcomes
between the transfemoral
and transapical approach
As shown in Figure 2, the survival rate was lower after TA than TF
TAVI. The difference in mortality occurred in the ﬁrst 6 months.
After 6 months of follow-up, the two survival curves began to
run parallel. Interestingly, the mortality rate in the TA cohort is
not consistent with a number of published series
22,24 which
deserves careful examination in order to identify the reasons for
this discrepancy. First, there was a substantial selection bias result-
ing from the inclusion of patients with a higher co-morbidity rate
........................................................ ........................................................
...............................................................................................................................................................................
Table 7 Causes of death within the ﬁrst-year post-implant (early: ≤30 days; late: 31–365 days)
Transapical Transfemoral
Early Late Total Early Late Total
Annulus dissection 1 0 1 0 0 0
Ventricular arrythmia 0 0 0 1 0 1
Cardiac failure 1 6 7 1 1 2
Bleeding 2 0 2 0 0 0
Multiple organ failure 1 3 4 2 0 2
Myocardial infarction 3 0 3 0 2 2
Severe paravalvular leak 1 0 1 0 0 0
Sepsis 0 3 3 1 0 1
Infection/Inﬂamation 0 2 2 0 1 1
Stroke 0 1 1 0 0 0
Sudden death 2 3 5 0 1 1
Cancer 0 1 1 0 0 0
Other 1 3 4 0 3 3
Unknown 1 0 1 0 0 0
................................................................................
Table 8 New York Heart Association over time
(transapical patients)
Value Baseline
(%)
30 Days
(%)
6 Months
(%)
1 Year
(%)
I 1 (1.4) 17 (30.4) 17 (42.5) 16 (47.1)
II 9 (13.0) 16 (28.6) 11 (27.5) 11 (32.4)
III 47 (68.1) 6 (10.7) 4 (10.0) 4 (11.8)
IV 12 (17.4) 3 (5.4) 0 (0.0) 1 (2.9)
Unknown 0 (0.0) 14 (25.0) 8 (20.0) 2 (5.9)
Total 69 56 40 34
................................................................................
Table 9 New York Heart Association over time
(transfemoral patients)
Value Baseline
(%)
30 Days
(%)
6 Months
(%)
1 Year
(%)
I 1 (1.6) 20 (35.7) 24 (43.6) 19 (39.6)
II 9 (14.8) 20 (35.7) 15 (27.3) 22 (45.8)
III 41 (67.2) 5 (8.9) 6 (10.9) 4 (8.3)
IV 10 (16.4) 0 (0.0) 0 (0.0) 1 (2.1)
Unknown 0 (0.0) 11 (19.6) 10 (18.2) 2 (4.2)
Total 61 56 55 48
T. Lefe `vre et al. 154(mainly peripheral disease) in the TA group. Furthermore, although
several complications of TAVI are common to both approaches,
TA TAVI requires thoracotomy, puncture of the apex and
introduction of a large sheath into the left ventricle, which may
lead to speciﬁc post-operative complications. Importantly, as the
current results represent early experiences with these devices,
better outcomes in the TA group are to be expected in the
future. Careful patient selection by avoiding, for example, patients
with severe respiratory failure, in addition to optimal training and
collaboration between the cardiac surgeon and the interventional
cardiologist, and optimal image quality in the operating room are
all required for successful TAVI outcomes using the TA approach.
Atrioventricular block
The incidence of complete atrioventricular block requiring pace-
maker implantation at ≤30 days was low (1.8% for the TF and
3.8% for TA approach), and is consistent with other reports on
the Edwards SAPIENTM valve prosthesis.
18–21,23 This incidence is
lower than that observed with the CoreValveTM device.
25,26 One
of the major differences between the two devices is the depth
of placement of the valve at the left ventricular outﬂow track
level. The CoreValveTM device is designed to be seated lower
than the SAPIENTM valve and may compress the underlying
conduction system.
Valve positioning
There was one ostial coronary obstruction secondary to valve
implantation which required stent implantation in the TA group.
This is a rare complication which may occur in  1% of
cases.
27,28 When the distance between the annulus and the coron-
ary ostia is short, the native valve may be pushed against the cor-
onary ostium by the THV. Positioning the valve too high or not
coaxial with the outﬂow track may increase this risk. In all cases,
excellent image quality when carrying out the TA and also TF
approach is crucial for identifying potential problems. No
device-induced mitral valve dysfunction was observed.
Valve embolization occurred in two TF and in one TA cases.
This is another infrequent complication which occurs in  1% of
cases.
28 Careful pre-procedure annulus measurements, stable
lead positioning for rapid pacing, optimal valve positioning, full
balloon inﬂation at the time of valve deployment, and complete
balloon deﬂation before stopping rapid pacing are of utmost
importance to prevent this complication.
...............................................................................................................................................................................
Table 10 Summary statistics for EQ-5D overall score (UK-TTO) and Kansas City Cardiomyopathy Questionnaire
overall summary scores
Type Delivery Visit n Overall score P-value
EQ-5D Transapical Baseline 20 0.59+0.30 0.1294
1 year 20 0.66+0.43
Transfemoral Baseline 31 0.57+0.32 0.3319
1 year 31 0.62+0.31
KCCQ Transapical Baseline 23 49.6+22.7 0.0004
1 year 23 77.1+23.4
Transfemoral Baseline 33 49.9+21.7 0.0002
1 year 33 67.9+23.7
................................................................................
Table 11 Summary statistics for valve performance
Type Delivery Visit n Value
EOA (cm
2) Transapical Baseline 47 0.6+0.2
6 months 25 1.4+0.4
1 year 18 1.6+0.5
Transfemoral Baseline 38 0.7+0.2
6 months 26 1.5+0.4
1 year 21 1.5+0.5
Mean gradient
(mmHg)
Transapical Baseline 58 47.2+18.9
6 months 31 10.6+6.9
1 year 23 11.5+3.9
Transfemoral Baseline 50 46.6+17.3
6 months 34 11.1+3.7
1 year 34 12.7+4.8
LVEF (%) Transapical Baseline 51 54+13.8
6 months 30 56.1+14.8
1 year 23 55.2+8.2
Transfemoral Baseline 46 53.2+18.4
6 months 29 56.2+16.1
1 year 29 56.3+13.0
Figure 3 Predicted 1 year mortality vs. Logistic Euroscore.
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Risk of stroke
The incidence of stroke at ≤30 days was relatively low, 1.5% in the
TA group and 3.3% in the TF group. This compares favourably with
the risk of peri-operative stroke following surgical AVR in elderly
patients ranging from 3 to 7%.
15,29,30 Careful patient selection,
device preparation, optimal device progression, and positioning,
as well as adequate antiplatelet pre-medication and anticoagulation
regimen are likely to reduce this risk.
Valve performance
Echocardiographic data have shown an immediate reduction in the
transvalvular gradient after valve implantation and, in the majority
of cases, no signiﬁcant AR. Furthermore, the initial increase in
EOA remained stable at 6- and 12-month follow-up. Finally,
there was no evidence of THV deterioration up to 1 year. The
SAPIENTM valve was explanted in one patient on Day +252 due
to valve thrombosis. Although the cause of thrombosis is
unknown, the fact that the patient discontinued aspirin and clopi-
dogrel 6 weeks post-procedure may have played a role.
Quality of life
Improvement in QoL and activities of daily living may well be the
most important beneﬁt of TAVI in this elderly population of
patients who prefer to add life to their years rather than years
to their life; 82.1% had an improvement in their NYHA class,
87.2% being in Class I or II. EQ-5D demonstrated marginal
improvement at 1 year post-intervention. However, this score is
not speciﬁc to this patient population and may not be an adequate
gauge. On the other hand, the KCCQ overall summary score,
which is speciﬁc for cardiac patients, demonstrated an important
treatment effect with 73.2% of patients experiencing a signiﬁcant
improvement from baseline to 1 year.
Study limitations
PARTNER EU embedded the ‘learning curve’ for most European
TAVI operators, compounded by the use of an earlier generation
delivery system which was more prone to complications. Unfortu-
nately, the number of patients included in the study is too small to
provide information about the role of the learning phase and pre-
dictors of complications. This study is not a randomized compari-
son of TA vs. TF approach, but a complementary approach.
Assessment of bioprosthetic valve durability will require longer-
term follow-up in PARTNER EU and other TAVI clinical trials.
Finally, when adjudicating events, the Clinical Events Committee
was not blinded to the procedure performed.
Conclusion
The results of this ﬁrst registry, PARTNER EU, conﬁrm the safety
and efﬁcacy of the Edwards SAPIENTM valve implanted in very
high-risk patients with severe aortic stenosis via either the TF or
the TA route, depending on the decision of the heart team. The
higher mortality rate observed in the TA group seems to be
mainly related to a selection bias. The use of this device and
similar devices mandates multi-specialty collaboration. Future
registries and randomized trials should provide a better deﬁnition
of the safety and durability aspects of both techniques.
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